Data Sheet (Cat.No.T9647)

TargetMol

GX 201

Chemical Properties



CAS No. : 1788071-27-1

Formula: C25H27ClF4N2O4S

Molecular Weight: 563

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	GX 201 is a selective NaV1.7 inhibitor, IC50 of < 3.2 nM for hNaV1.7.
Targets(IC50)	Sodium Channel
In vivo	GX 201 has a relatively long half-life in mice. GX 201 produces analgesia at a free plasma concentration about 3 times the IC50 for high-affinity channel block. GX 201 inhibits nociceptive responses induced by formalin and inflammatory pain caused by complete Freund's adjuvant (CFA)[1].

Solubility Information

Solubility	DMSO: 5.63 mg/mL (10 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (1.78 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7762 mL	8.881 mL	17.762 mL
5 mM	0.3552 mL	1.7762 mL	3.5524 mL
10 mM	0.1776 mL	0.8881 mL	1.7762 mL
50 mM	0.0355 mL	0.1776 mL	0.3552 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Girish Bankar, et al. Selective Na V 1.7 Antagonists with Long Residence Time Show Improved Efficacy against Inflammatory and Neuropathic Pain. Cell Rep. 2018 Sep 18;24(12):3133-3145.